Adicet Bio Appoints Julie Maltzman As CMO
(RTTNews) - Adicet Bio, Inc. (ACET), a company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, said on Wednesday that it has appointed Julie Maltzman as Chief Medical Officer with effect from January 13, 2025.
She will succeed Francesco Galimi, who has completed his tenure at Adicet this month.
Maltzman joins Adicet from IconOVir Bio, where she served as Chief Medical Officer.
Earlier, she worked as the VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.